Hunan Yongren Medical Innovation Co. Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2016
NCT03060343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Hunan Zhaotai Yongren Medical Innovation Co. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous natural killer cells (1 trial)

Drugs in Phase 1 Trials (2)

cytotoxic t cells (1 trial)

gpc3 and/or tgfβ targeting car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3